Diabetes Landscape: Market, Technology And Intellectual Property
Use this report to...
Understand the drivers of this US$12.4 billion industry Appreciate the value of monitoring and treatment markets Know the market share of leading companies such as J&J, Abbott, Bayer, Becton Dickinson and Medtronic Assess new technologies and treatments which will change the diabetes market Access detailed patent and technology analysis for the detection, treatment and monitoring of diabetes Understand the emerging trends and commercialisation status Compare and contrast the technology portfolio in major companies through their patent activities Drill down into intellectual property trends in the diabetes device sector and see how they relate to market opportunities.
Who should read this report Intellectual Property Professionals Technology Licensing Specialists Product Development Executives Product and Marketing Managers CTOs and Technical Managers Researchers working in the diabetes space Component Manufacturers
A high growth and resilient marketThe diabetes care market has historically exhibited strong growth, leading global sales volumes to have increased from US$8.6 billion in 2005 to US$12.4 billion in 2011. This increase is generally being driven by the increasing prevalence of diabetes, the introduction of higher-priced newer technologies such as continuous glucosemonitoring, changing trends in the management of diabetes, and the development of healthcare systems of emerging markets in recent years.Having experienced strong annual growth in the period before 2009, the market slowed considerably, rising by just 1% in that year and by 2% in 2010. Although most product areas continued to generate strong sales volumes, this lower growth was due to weakness in the self monitoring blood glucose market as a result of lower sales volumes and pricing pressure in the US due to the economic slowdown. Since 2010, the diabetes care market has once again picked up, rising by 6% in 2011. This improvement has been due to renewed growth for self monitoring blood glucose (SMBG) products, helped by new product launches in the US but, mainly due to strong demand in emerging markets. The growth rates in the insulin delivery segmentslowed slightly during the year due to pricing pressure for pen needles and a slight slowdown in insulin pump sales as a result of the negative economic environment.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts